The estimated Net Worth of Dominique Monnet is at least $2.66 Billion dollars as of 16 December 2020. Mr. Monnet owns over 500,000 units of PDL Biopharma Inc stock worth over $2,650,125,126 and over the last 10 years he sold PDLI stock worth over $1,397,198. In addition, he makes $6,701,000 as President, Chief Executive Officer, and Director at PDL Biopharma Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Monnet PDLI stock SEC Form 4 insiders trading
Dominique has made over 3 trades of the PDL Biopharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 500,000 units of PDLI stock worth $1,300,000 on 16 December 2020.
The largest trade he's ever made was selling 500,000 units of PDL Biopharma Inc stock on 16 December 2020 worth over $1,300,000. On average, Dominique trades about 45,507 units every 194 days since 2015. As of 16 December 2020 he still owns at least 734,921 units of PDL Biopharma Inc stock.
You can see the complete history of Mr. Monnet stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dominique Monnet biography
Dominique Monnet has been appointed President, Chief Executive Officer, Director of the Company. Before joining the Company, Mr. Monnet served as senior vice president and chief marketing officer of Alexion Pharmaceuticals from May 2014 to October 2015 where he was responsible for commercial operations in the United States and Latin America and oversaw new products and global business operations functions. From August 2013 to May 2014 he was a managing director at Biotech Advisors International, LLC, a biotechnology consulting firm. Prior to that, from July 2002 through July 2013, he was a senior executive at Amgen Inc. (“Amgen”) where he served in a number of key commercial leadership positions in the United States and internationally. Most recently he acted as vice president and general manager for Amgen’s Inflammation Business Unit from August 2011 until July 2013, where he was responsible for accelerating the growth of the Enbrel® franchise in the highly competitive U.S. market. Prior to this, he served as vice president and head of Amgen’s Global Marketing and Commercial Development, where he led the marketing strategies and global launches of new products across a range of therapeutic areas. From July 2002 through 2006, Mr. Monnet was based in Zug, Switzerland, where he served as Amgen’s vice president of International Marketing and Business Operations, building Amgen’s international commercial capability and leading the creation of its successful international franchises in oncology and nephrology. Before joining Amgen, Mr. Monnet held positions of increasing responsibility in line commercial management and global marketing over 19 years at Schering-Plough - including General Manager of its affiliate in the UK and Republic of Ireland - Ciba-Geigy and Alza Corporation. Mr. Monnet holds a business degree from EDHEC Business School in Lille, France, and an M.B.A. from INSEAD in Fontainebleau, France.
What is the salary of Dominique Monnet?
As the President, Chief Executive Officer, and Director of PDL Biopharma Inc, the total compensation of Dominique Monnet at PDL Biopharma Inc is $6,701,000. There are no executives at PDL Biopharma Inc getting paid more.
How old is Dominique Monnet?
Dominique Monnet is 61, he's been the President, Chief Executive Officer, and Director of PDL Biopharma Inc since 2018. There are 2 older and 5 younger executives at PDL Biopharma Inc. The oldest executive at PDL Biopharma Inc is John McLaughlin, 68, who is the Director.
What's Dominique Monnet's mailing address?
Dominique's mailing address filed with the SEC is 932 SOUTHWOOD BLVD., , INCLINE VILLAGE, NV, 89451.
Insiders trading at PDL Biopharma Inc
Over the last 22 years, insiders at PDL Biopharma Inc have traded over $45,966,964 worth of PDL Biopharma Inc stock and bought 12,693,393 units worth $32,804,545 . The most active insiders traders include Point Capital L.P.O'shea Ro..., Faheem Hasnain, and Laurence Jay Korn. On average, PDL Biopharma Inc executives and independent directors trade stock every 24 days with the average trade being worth of $245,074,578. The most recent stock trade was executed by Point Capital L.P.O'shea Ro... on 1 February 2021, trading 187,061 units of PDLI stock currently worth $383,475.
What does PDL Biopharma Inc's logo look like?
Complete history of Mr. Monnet stock trades at Alexion Pharmaceuticals and PDL Biopharma Inc
PDL Biopharma Inc executives and stock owners
PDL Biopharma Inc executives and other stock owners filed with the SEC include:
-
Dominique Monnet,
President, Chief Executive Officer, Director -
Christopher Stone,
Vice President, General Counsel, Secretary -
Edward Imbrogno,
Chief Financial Officer, Chief Accounting Officer, Vice President - Finance -
John McLaughlin,
Director -
David Gryska,
Independent Director -
Elizabeth O'Farrell,
Chairperson of the Board -
Natasha Hernday,
Independent Director -
Alan Bazaar,
Independent Director -
Danny J Jr. Hart,
Assoc Genl Counsel/Asst Sec -
Samuel R Saks,
Director -
Jody S Lindell,
Director -
Paul R Edick,
Director -
Harold E Selick,
Director -
Paul W Sandman,
Director -
Peter S Garcia,
Vice President, CFO -
Steffen Pietzke,
Controller and CAO -
Shlomo Yanai,
Director -
Jill M. Jene,
VP, Business Development -
Christine R Larson,
VP & Chief Financial Officer -
Joseph Iii Klein,
Director -
Karen J Wilson,
VP of Finance & PAO -
Mark Anthony Mc Camish,
SVP & CMO -
Brett L Schmidli,
SVP, Technical Operations -
Gary A Lyons,
Director -
Andrew Guggenhime,
SVP & Chief Financial Officer -
Faheem Hasnain,
President & CEO -
Francis Willard Sarena,
Exec Dir/Chief Legal Off/Secy -
Herb Cross,
Corp Controller/Prin Acctg Off -
Richard /Ca/ Murray,
Sr. VP & CSO -
Steven E Benner,
SVP and Chief Medical Officer -
Bradford S Goodwin,
Director -
Laurence Jay Korn,
Chairman of the Board -
Karen A Dawes,
Director -
Jaisim Shah,
Vice President, Marketing -
Jon S Saxe,
Director -
L Patrick Gage,
Director -
Glen Y Sato,
SVP and CFO -
Cynthia Lynn Shumate,
VP Legal Affrs, Secy & CCO -
Cary L Queen,
Senior Vice President -
Peter H Calcott,
VP, Quality & Compliance -
Laurie C Torres,
VP, Human Resources -
David Iwanicki,
VP, Sales & Sales Operations -
Mark Mcdade,
Chief Executive Officer -
Robert Michael Ii Savel,
SVP Technical Operations -
Samuel Broder,
Director -
George Jue,
VP, Fin & Corp. Controller -
Max Link,
Director -
Sergio Garcia Rodriguez,
VP, Legal and General Counsel -
Lyn D Olson,
VP, Quality and Compliance -
Douglas O Ebersole,
SVP, Legal & Corp Development -
George M Gould,
Director -
Jurgen Drews,
Director -
Behrooz Najafi,
V.P. IS and Corporate Services -
Corine Klingbell,
VP, Preclinical Development -
William R Benjamin,
VP, Research & Clinical Tech -
Frances G Charlson,
VP, Human Resources -
Patrick M Caldwell,
VP, Finance and Controller -
Mark P Backer,
VP, Technical Development -
David Montez,
Controller and CAO -
Fred Frank,
Director -
Bruce Tomlinson,
Chief Financial Officer -
Caroline J Krumel,
Vice President of Finance -
Point Capital L.P.O'shea Ro...,